publication . Article . 2009


Solórzano-Santos, Fortino; Miranda-Novales, Ma. Guadalupe;
Open Access Spanish
  • Published: 01 Oct 2009
  • Publisher: Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez
La influenza es una infección viral aguda de las vías respiratorias, altamente contagiosa. Es causada por el virus de la influenza A, B y C. Puede afectar a todos los grupos etarios durante epidemias, aunque tiene mayor morbilidad en los extremos de la vida. La enfermedad frecuentemente requiere de atención médica y hospitalización, contribuyendo sustancialmente a pérdidas económicas, exceso en el número de días/cama-hospital y muertes. Considerando la epidemia reciente en México del virus de la influenza humana H1N1, y la presencia de brotes epidémicos estacionales, se presenta esta actualización, haciendo énfasis en los aspectos de prevención y tratamiento. In...
Medical Subject Headings: virusesvirus diseases
free text keywords: Influenza, prevención, vacuna de influenza, virus de influenza H1N1, prevention, influenza vaccine, H1N1 influenza A virus
17 references, page 1 of 2

1. Cox NJ, Subbarao K. Influenza. Lancet. 1999; 354: 1277-82. 18. Rothberg RB, Haessler SD, Brown RB. Complications of

2. Osterholm MT. Preparing for the next pandemic. N Engl viral influenza. Am J Med. 2008; 121: 258-64. J Med. 2005; 352: 1839-41. 19. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein

3. Forsberg-White L, Pagano M. Transmissibility of the in- S, Hayden FG, et al. Seasonal influenza in adults and fluenza virus in the 1918 pandemic. Available from: PLoS children - Diagnosis, treatment, chemoprophylaxis, and ONE 3(1): e1498. doi:10.1371/journal.pone.0001498. institutional outbreak management: Clinical Practice

4. CDC. Update: Influenza activity - United States, 2003- Guidelines of the Infectious Diseases Society of Ameri2004 Season. MMWR Morb Mortal Wkly Rep. 2004; ca. CID. 2009; 48: 1003-32. 52: 1197-202. 20. CDC. Prevention and control of influenza. Recommen-

5. Kilbourne ED. Influenza pandemics of the 20th century. dations of the Advisory Committee on Immunizations Emerg Infect Dis. 2006; 12:.9-14. Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2008- [OpenAIRE]

6. Kilbourne ED. Influenza pandemics: can we prepare for 2009. the unpredictable? Viral Immunol. 2004; 17: 350-7. 21. MacIntyre CR, Cauchemez S, Dwyer DE, Seale H, Che-

7. Kuri-Morales P, Galván F, Cravioto P, Zárraga-Rosas LA, ung P, Browne G, et al. Face -mask use and control of Tapia-Conyer R. Mortalidad en México por influenza y neu- respiratory virus transmission in households. Emerg Inmonía (1990-2005). Salud Publica Mex. 2006; 48: 379-84. fect Dis. 2009; 15: 233-41.

8. Trifonov V, Khiabanian H, Rabadan P. Geographic de- 22. Hayden FG. Antivirals for influenza: Historical perspectipendence, surveillance, and origins of the 2009 influenza ves and lessons learned. Antiviral Res. 2006; 71: 372-8. A (H1N1) virus. N Engl J Med. Available from: 10.1056/ 23. Shiraishi K, Mitamur K, Sakai-Tagawa Y, Goto H, Sugaya nejmp0904572. N, Kawaoka Y. High frequency of resistant viruses har-

9. boring different mutations in amantadine-treated chil-

10. CDC. Swine influenza A (H1N1) infection in two chil- dren with influenza. J Infect Dis. 2003; 188: 57-61. dren-Southern California, March-April 2009. MMWR 24. Jefferson T, Demicheli V, Rivetti D, Jones M, Di PietranMorb Mortal Wkly Rep. 2009; 58: 400-2. tonj C, Rivetti A. Antivirals for influenza in healthy adul-

11. CDC. Outbreak of swine-origin influenza A (H1N1) vi- ts: systematic review. Lancet. 2006; 367: 303-13. rus infection-Mexico, March-April 2009. MMWR Morb 25. CDC. Antiviral agents for influenza: Background inforMortal Wkly Rep. 2009; 58: 467-70. mation for clinicians. Available from:

12. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Ker- flu/professionals/antiviralback.htm khove M, Hollingsworth TD, et al., and the WHO Pan- 26. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kanazawa H, demic Assessment Collaboration. Pandemic potential of Kawashima T, et al. A comparison of the effectiveness a strain of influenza A (H1N1): Early findings. Available of zanamivir and oseltamivir for the treatment of infrom: fluenza A and B. J Infect. 2008; 56: 51-7. science.1176062 27. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami

13. Dirección General de Epidemiología: Anuarios de Mor- Ch, Kawaoka Y, et al. Comparison of the clinical effectibilidad. Disponible en: Acce- veness of oseltamivir and zanamivir against influenza viso: Junio 4, 2009. rus infection in children. CID. 2008; 47: 339-45.

14. General Directorate of Epidemiology, Ministry of Health, 28. Monto AS, McKimm-Breschkin JL, Macken C, Hampson Mexico; Pan American Health Organization; World Heal- AW, Hay A, Klimov A, et al. Detection of influenza viruth Organization; Public Health Agency of Canada; Influenza ses resistant to neuraminidase inhibitors in global surDiv., National Center for Immunization and Respiratory veillance during the first 3 years of their use. Antimicrob Diseases, CDC Influenza Emergency Response Team. Agents Chemother. 2006; 50: 2395-402. Update: Novel Influenza A (H1N1) Virus Infections - 29. Escuret V, Frobert E, Buscambert-Duchamp M, Sabatier Worldwide, May 6, 2009. May 8, 2009/Vol. 58/No. 17. M, Grog I, Valette M, et al. Detection of human influenza

15. Patrozou E, Mermel L. Does influenza transmission oc- A (H1N1) and B strains with reduced sensitivity to neucur from asymptomatic infection owrpwriorwto.smympetodmigraphramicini.dcaseoinmhibitors. J Clin Virol. 2008; 41: 25-8. onset? Public Health Rep. 2009; 124: 193-6. 30. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention

17 references, page 1 of 2
Any information missing or wrong?Report an Issue